Reimbursement and Support

We focus on access so you can focus on health.

At Genentech and Biogen Idec, we develop therapies for serious or life-threatening medical conditions and we believe they should be accessible for the patients who need them.

Rituxan® Access Solutions is here to help you and your patients when a Genentech medicine is prescribed. Our knowledgeable and experienced Specialists can help you navigate the access and reimbursement process. Each patient’s insurance and financial situation is unique. We offer a full range of programs and services to meet the needs of you and your patients.

Rituxan Access Solutions: Service structure

COVERAGE AND REIMBURSEMENT PATIENT ASSISTANCE INFORMATIONAL RESOURCES
  • Help with benefits and coverage issues
    • Benefits investigation
    • Prior authorization
    • Recertification
  • Help with reimbursement issues
    • Denials and appeals
    • Billing and coding information
  • Genentech® Access to Care Foundation (GATCF) support for qualifying uninsured and rendered uninsured patients
  • Referrals to independent, non-profit organizations for co-pay assistance
  • Genentech BioOncology Co-pay Card
  • CancerCare
  • My Patient Solutions, our online patient management tool
  • Communication assistance services
    • Translation services
    • Telephone to telephone typewriter (TTY) services
  • Product spoilage and replacement information
  • Medicare/Medicaid search tool
  • Glossary of access and reimbursement terms
  • The Genetech BioOncology Co-pay Card helps eligible patients reduce their out-of-pocket co-pay expenses
  • CancerCare is a leading nation non-profit organization offering counseling, education and practical help free of charge to anyone affected by cancer

At Rituxan Access Solutions, we work hard to make information you need about coverage and reimbursement easily available:

  • Via phone between the hours of 6 am and 5 pm PT Monday through Friday:
    • (888) 249-4918
  • On our Web site, 24 hours a day, every day:
Copay Card

Genentech BioOncology Co-pay Card

See if your patients are eligible.

View Now
Prescribing Information including Medication Guide

Prescribing Information including Medication Guide (PDF)

Attention Healthcare Provider: Provide Medication Guide to patient prior to RITUXAN infusion.

Indications

RITUXAN® (Rituximab) is indicated for the treatment of patients with:

  • Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
  • Previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to RITUXAN in combination with chemotherapy, as single-agent maintenance therapy
  • Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
  • Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
  • Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC)

RITUXAN is not recommended for use in patients with severe, active infections.

Important Safety Information

WARNING: FATAL INFUSION REACTIONS, TUMOR LYSIS SYNDROME (TLS), SEVERE MUCOCUTANEOUS REACTIONS, and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)

Infusion Reactions: RITUXAN administration can result in serious, including fatal, infusion reactions. Deaths within 24 hours of RITUXAN infusion have occurred. Approximately 80% of fatal infusion reactions occurred in association with the first infusion. Carefully monitor patients during infusions. Discontinue RITUXAN infusion and provide medical treatment for Grade 3 or 4 infusion reactions.

Tumor Lysis Syndrome (TLS): Acute renal failure requiring dialysis with instances of fatal outcome can occur in the setting of TLS following treatment of non-Hodgkin's lymphoma (NHL) with RITUXAN monotherapy.

Severe Mucocutaneous Reactions: Severe, including fatal, mucocutaneous reactions can occur in patients receiving RITUXAN.

Progressive Multifocal Leukoencephalopathy (PML): JC virus infection resulting in PML and death can occur in patients receiving RITUXAN.

Warnings and Precautions

RITUXAN has also been associated with other serious and/or fatal adverse reactions. These include

  • hepatitis B reactivation with fulminant hepatitis; hepatic failure resulting in death
  • serious, including fatal, bacterial, fungal, and new or reactivated viral infections
  • cardiovascular events, including serious or life-threatening cardiac arrhythmias
  • severe, including fatal, renal toxicity
  • abdominal pain, bowel obstruction and perforation, in some cases leading to death, can occur in patients receiving RITUXAN in combination with chemotherapy

Additional Important Safety Information

  • The most frequent Grade 3 or 4 adverse reactions observed in NHL were cytopenias, including lymphopenia. The most common adverse reactions of RITUXAN (incidence ≥25%) observed in clinical trials of patients with NHL were infusion reactions, fever, lymphopenia, chills, infection, and asthenia. The incidence of infusion reactions was highest during the first infusion (77%) and decreased with each subsequent infusion. These infusion reactions typically resolved with slowing or interruption of the infusion and with supportive care
  • The most common adverse reactions of RITUXAN (incidence ≥25%) observed in clinical trials of patients with CLL were infusion reactions and neutropenia. Infusion-related adverse reactions occurring during or within 24 hours of the start of infusion included nausea, pyrexia, chills, hypotension, vomiting, and dyspnea
  • Most CLL patients treated with R-FC experienced at least one Grade 3 or 4 adverse reaction. The Grade 3 or 4 adverse reactions observed more frequently with R-FC compared with FC alone were neutropenia, leukopenia, febrile neutropenia, thrombocytopenia, infusion reactions, pancytopenia, hypotension, and hepatitis B
  • In clinical trials, CLL patients 70 years of age or older who received R-FC had more Grade 3 and 4 adverse reactions compared with younger CLL patients who received the same treatment

For additional safety information, please see the full prescribing information, including BOXED WARNINGS and Medication Guide.

Attention Healthcare Provider: Provide Medication Guide to patient prior to RITUXAN infusion.